Last reviewed · How we verify

METRIZOATE MAGNESIUM

FDA-approved approved Small molecule Quality 2/100

Metrizoate Magnesium is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it maintains relevance due to its current market presence. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameMETRIZOATE MAGNESIUM
ModalitySmall molecule
PhaseFDA-approved
First approval1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions